16 May 2021
Xbrane announces ambition to generate positive operating cash flow monthly by late 2023/early 2024 and to initiate one new biosimilar development program per annum.
04 May 2021
Invitation to presentation of Xbrane Biopharma’s interim report January – March, 2021 on May 6, 2021.
15 Apr 2021
Xbrane Biopharma expands in-house Biosimilar development capabilities with new Biotech lab and invites participants to Virtual Capital Markets day on May 17.
15 Mar 2021
Xbrane strengthens the organization with the appointment of Erik Domines as General Counsel
24 Feb 2021
To further focus on becoming a world leading biosimilar developer Xbrane enters a non-binding term-sheet to divest its Italian subsidiary Primm Pharma
11 Jan 2021
Xbrane appoints Anette Lindqvist as new Chief Financial Officer & Head of Investor Relations